ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)

Phase 2Recruiting

1 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Generalized Anxiety Disorder (GAD)

Conditions

Generalized Anxiety Disorder (GAD)

Trial Timeline

Apr 29, 2025 → Nov 1, 2026

NCT ID

NCT06846320

About ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)

ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT) is a phase 2 stage product being developed by AbbVie for Generalized Anxiety Disorder (GAD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06846320. Target conditions include Generalized Anxiety Disorder (GAD).

What happened to similar drugs?

12 of 20 similar drugs in Generalized Anxiety Disorder (GAD) were approved

Approved (12) Terminated (3) Active (7)

✅Duloxetine + PlaceboEli LillyApproved

✅IxekizumabEli LillyApproved

✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved

✅EscitalopramAbbVieApproved

✅QuetiapineAstraZenecaApproved

✅Alprazolam (Xanax) + PlaceboRocheApproved

✅Ziprasidone + PlaceboPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06846320	Phase 2	Recruiting	Apr 29, 2025	Nov 1, 2026	Generalized Anxiety Disorder (GAD)

Competing Products

20 competing products in Generalized Anxiety Disorder (GAD)

See all competitors

Product	Company	Stage	Hype Score
atomoxetine + placebo	Eli Lilly	Phase 2/3	38
Satralizumab	Chugai Pharmaceutical	Phase 3	32
Perampanel	Eisai	Pre-clinical	26
Perampanel + Placebo comparator	Eisai	Phase 3	40
zonisamide	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Perampanel	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
Cenobamate	Ono Pharmaceutical	Phase 3	47
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Approved	43
Ixekizumab	Eli Lilly	Approved	43
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	35
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment	Sumitomo Pharma	Approved	43
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	27
ABBV-932 + Placebo	AbbVie	Phase 1	29
Escitalopram	AbbVie	Approved	43
Adalimumab	AbbVie	Phase 3	40
Quetiapine fumarate + Paroxetine	AstraZeneca	Phase 3	40